Impact of adalimumab treatment on health-related quality of life and other patient-reported outcomes: results from a 16-week randomized controlled trial in patients with moderate to severe plaque psoriasis
- 28 November 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 158 (3), 549-557
- https://doi.org/10.1111/j.1365-2133.2007.08236.x
Abstract
Health-related quality of life (HRQOL) and other patient-reported outcomes (PROs) are important in evaluating the impact of psoriasis and its treatment. To assess the impact of adalimumab treatment on HRQOL and other PROs in patients with moderate to severe psoriasis. A 16-week, double-blind, double-dummy, randomized controlled trial evaluated the efficacy and safety of adalimumab in 271 adults with moderate to severe chronic plaque psoriasis. Patients were randomized in a 2:2:1 ratio to adalimumab, methotrexate (MTX) or placebo. PROs were evaluated throughout the study and included the Dermatology Life Quality Index (DLQI), Patient's Global Assessment of disease severity, plaque psoriasis and psoriatic arthritis pain visual analogue scale (VAS), Psoriasis-Related Pruritus Assessment and EuroQOL 5D (EQ-5D). Statistically significant differences were observed between the adalimumab- and placebo-treated and the MTX-treated groups on mean DLQI total scores during the 16-week double-blind study (both P<0.001). Significant differences, favouring adalimumab compared with placebo, were also observed on the Patient's Global Assessment of disease severity (P<0.001), VAS for pain (P<0.001), Psoriasis-Related Pruritus Assessment (P<0.001), EQ-5D VAS (P<0.001) and EQ-5D index score (P<0.01). Compared with MTX, adalimumab resulted in statistically significantly greater improvements in the Patient's Global Assessment of disease severity (P<0.001), the VAS for pain (P<0.01) and the Psoriasis-Related Pruritus Assessment (P<0.001). Adalimumab was efficacious in improving dermatology-specific HRQOL, disease control and symptom outcomes in patients with moderate to severe psoriasis.Keywords
This publication has 30 references indexed in Scilit:
- PsoriasisNew England Journal of Medicine, 2005
- Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasisBritish Journal of Dermatology, 2004
- Quantifying the harmful effect of psoriasis on health-related quality of lifeJournal of the American Academy of Dermatology, 2002
- Social coping strategies associated with quality of life decrements among psoriasis patientsBritish Journal of Dermatology, 2001
- The impact of psoriasis on quality of lifeBritish Journal of Dermatology, 2001
- Two considerations for patients with psoriasis and their clinicians:: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?Journal of the American Academy of Dermatology, 2000
- Psoriasis causes as much disability as other major medical diseasesJournal of the American Academy of Dermatology, 1999
- Quality of life assessments in dermatologySeminars in Cutaneous Medicine and Surgery, 1998
- The Impact of Psoriasis on Psychosocial Life DomainsScandinavian Journal of Caring Sciences, 1997
- POPULATION-BASED EPIDEMIOLOGIC STUDY OF PSORIASIS WITH EMPHASIS ON QUALITY OF LIFE ASSESSMENTDermatologic Clinics, 1996